Printer Friendly

Oncopeptides announces presentation of first interim data from the ongoing combination trial ANCHOR at the 60th ASH meeting.

NORDIC BUSINESS REPORT-December 3, 2018-Oncopeptides announces presentation of first interim data from the ongoing combination trial ANCHOR at the 60th ASH meeting

(C)2018 M2 COMMUNICATIONS http://www.m2.com

Oncopeptides AB (STO:ONCO), a pharmaceutical company developing drugs for the treatment of cancer, announced on Friday a presentation of the first interim data with melflufen (Ygalo) from the ongoing phase I/II study ANCHOR, at the 60th American Society of Haematology (ASH) meeting in San Diego, California, US.

According to the company, the overall conclusions from the interim adapt are that the combinations of melflufen and dexamethasone (dex) with either bortezomib or daratumumab in relapsed-refractory multiple myeloma (RRMM) patients are well tolerated.

Also, no dose limiting toxicity has been observed at the melflufen 30 and 40 mg dose levels in either regimens. The 40 mg dose level is still recruiting patients

In addition, an Overall Response Rate (ORR) of 86% was observed with melflufen and dexamethasone in combination with daratumumab (CD38-directed monoclonal antibody) and an Overall Response Rate (ORR) of 100% was observed with melflufen and dexamethasone in combination with bortezomib (proteasome inhibitor)

According to the company, this interim data show a very good efficacy profile for melflufen in combination with either bortezomib or daratumumab. In a cross-study, comparison in RRMM patients treated with combination regimens our interim data with an ORR in the range 86 -100% stand out positively.

ANCHOR is a phase I/II study where melflufen and dexamethasone (dex) is dosed in combination with either bortezomib or daratumumab. All patients must have one to four prior lines of therapy and be refractory (or intolerant) to an immunomodulary agent (IMiD) or a proteasome inhibitor (PI) or both.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Nordic Business Report
Date:Dec 3, 2018
Words:291
Previous Article:NGEx Resources reports on increase in number of shares.
Next Article:Lundin Mining reports on increase in voting rights and capital.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters